Drug Profile
K 11050
Latest Information Update: 12 Oct 2006
Price :
$50
*
At a glance
- Originator Celera Genomics Group
- Class Antineoplastics
- Mechanism of Action Cysteine endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glioma
Most Recent Events
- 12 Oct 2006 Discontinued - Preclinical for Glioma in USA (unspecified route)
- 30 May 2001 Profile reviewed but no significant changes made
- 14 Nov 1997 No-Development-Reported for Glioma in USA (Unknown route)